The race to treat Ebola is on!
Right now it appears that a small US company with just nine employees is leading the race.
According to Bloomberg, Mapp Biopharmaceutical Inc has developed a treatment that has already been used on two US citizens who contracted Ebola while working at Ebola treatment stations in West Africa.
And so far, the results look hopeful. Both patients are showing signs of recovery, a good thing when dealing with a disease that can kill in less than two weeks.
But two patients are not enough to claim a cure.
And pharmacological companies around the world are rapidly testing different treatments to either contain or vaccinate against Ebola.
And as an investor, one thing’s for sure…
You need to know which company to back in this race
Now you might be thinking, how do you invest in a company like Mapp Biopharmaceutical Inc?
Unfortunately, for the most part you can’t. The company is a closed company that’s not publically traded. But that doesn’t mean you can’t profit.
You see, although the company that discovers a cure for a deadly disease is usually the one that makes the biggest profits, it’s not the only one.
That’s because, often these companies will license out their patented discoveries to allow other companies to produce the vaccines or treatments.
And this means that as an investor, you can buy shares in a pharmaceutical company with drug production facilities. These companies are the most likely to profit no matter who discovers the cure for Ebola or any other dreaded disease for that matter.
Looking at our local market, there isn’t a massive selection of pharma companies to invest in. But for my money I like Aspen Holdings (JSE: APN). The company has good international backing and an aggressive growth plan which could see you bank great gains over the
next few years.
On the international scene, a company to look out for is Cipla International. This company already has strong routing in Africa and India.
And it’s has good expertise producing vaccines and drugs like Anti Retro Virals to treat AIDS.
This positions the company well as a distributor of drugs to treat Africa.
So keep a close eye on the news headlines to see who’s leading the race to treat Ebola. And when a clear winner emerges, look for the companies that’ll help get that drug to the people who need it.
Do this, and you’ll be on your way to great profits.
After all, the scarier the disease, the more people will pay for a cure.
Until next time,
Here’s to staying ahead of the game.